A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Clinical trial NCT04644770 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04644770
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-12
- Primary completion
- 2026-12-08
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.